Market Overview

Immunogen Shares Charge Higher Following News of Deal with Lilly for TAP Technology

Related IMGN
2 Biotech Stocks That Beat The Market Last Week
Wednesday's Biggest Movers
Related LLY
Stocks Lower As Earnings Season Takes Back Seat To Geopolitical Uncertainties
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Eli Lilly Bets Big on Diabetes, Cancer Drugs (Fox Business)

Immunogen (NASDSAQ: IMGN) shares are rallying in early-afternoon trade Wednesday following a Form 8-K just filed with the SEC.

From the filing: "On August 26, 2013, ImmunoGen, Inc. (referred to as “we,” “us” or the “Company”) entered into a license agreement with Eli Lilly and Company (NYSE: LLY) (“Lilly”) granting Lilly rights to use our maytansinoid-based Targeted Antibody Payload (TAP) technology to develop and commercialize products directed to a specific antigen target on an exclusive basis. This license was granted pursuant to the terms of an existing Multi-Target Agreement entered into by the Company and Lilly in 2011. In accordance with the terms of the Multi-Target Agreement, execution of the license agreement entitles us to receive development, regulatory and sales milestone payments potentially totaling $200.5 million, as well as royalties on the commercial sales of any resultant products."

Posted-In: News Movers

 

Most Popular

Related Articles (LLY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters